Learning Centre

Regulation of biopharmaceuticals, tissue engineering and biogenerics : key issues for the developer

 |  Login

Show simple item record

dc.contributor Aalto-yliopisto fi
dc.contributor Aalto University en
dc.contributor.author Oila, Outi
dc.date.accessioned 2012-02-17T06:59:23Z
dc.date.available 2012-02-17T06:59:23Z
dc.date.issued 2005-06-03
dc.identifier.isbn 951-22-7650-X
dc.identifier.issn 1236-2697
dc.identifier.uri https://aaltodoc.aalto.fi/handle/123456789/2566
dc.description.abstract The objective of the present study is to examine the effect of regulation on development of new biopharmaceuticals, tissue engineering and biogenerics. This includes defining key issues, which may influence the outcome of receiving marketing authorization. Most of the results are based on interviews conducted with experts with different backgrounds: regulators, representatives of biocompanies, investors, researchers and representatives of trade associations. Product information retrievable from the homepages of the EMEA and FDA has also been used as a data source. A review article is also included as it highlights central issues of the thesis and contains new information in addition to the review data. Integration of regulation from the very early stages of product development and a sound understanding of regulatory requirements will have a positive impact on product development. However, detailed regulation is not necessarily available as new technologies push forth. This often leads to case-by-case evaluation, which is demanding and time consuming for both product developer and regulator. Tissue engineering is an example of such emerging technologies for which the regulation is still immature or lacking. According to the present study, a centralised evaluation seems the only possible route for ensuring uniform assessment of tissue engineering products. Currently product developers should develop products according to the medicinal products legislation, which also applies to biopharmaceuticals. Risk assessment and management is essential for Tissue engineering as the risks of these technologies are generally regarded as being substantial. Biogenerics, called similar biological medicinal products in the EU legislation, are and have been in the focus of heated debate in the EU and USA although generics may be regarded as an inevitable step of the technological cycle. The pivotal regulatory issue is the question of comparability, for which the present study reflected no agreement. Control of post-translational modifications, immunogenicity and the extent of clinical trials required by the regulators pose major challenges for the biogenerics manufacturers. Thus, at the present time, biogenerics should be regulated on a case-by-case basis. Data from this thesis shows that intensified monitoring of the safety prof11e is called for. It is evident that risks of biotechnology-derived products are different from small chemical entities. This should lead to focused risk management programs. The main risk is the transmission of infectious agents. From the regulatory point of view, the risk management of biologicals is currently far from optimal as the appropriate legislation lags behind. The SPCs (Summary of Product Characteristics) of the EMEA and the PIs (Package Inserts) of the FDA of 32 approved biopharmaceuticals were compared. A general observation was that the EU SPC is more detailed in its instructions and the approach to safety information was clearly stricter. This difference may reflect the approaches to risk management of new medicinal products by the two agencies. Consequently, in spite of increasing harmonisation of the regulatory requirements, there are significant differences between the regulatory approaches that should be taken into consideration in drafting clinical development plans for biopharmaceuticals for global market. en
dc.format.extent 60, [app]
dc.format.mimetype application/pdf
dc.language.iso en en
dc.publisher Helsinki University of Technology en
dc.publisher Teknillinen korkeakoulu fi
dc.relation.ispartofseries Applied biochemistry and microbiology report en
dc.relation.haspart Nieminen, O., Rahkamo, L. and Nordström, K., 2004. Biotechnology regulation: views of the authorities, investors, and product developers in Finland. Drug Information Journal 38, pages 253-264.
dc.relation.haspart Nieminen, O., Kurki, P. and Nordström, K., 2004. Tissue engineering: viable technologies seeking regulation – a Finnish perspective. Drug Discovery Today 9 (9), pages 387-391.
dc.relation.haspart Nieminen, O. and Kurki, P., 2004. Risk management for biological products. International Journal of Pharmaceutical Medicine 18 (3), pages 149-157.
dc.relation.haspart Nieminen, O. and Nordström, K., 2004. Regulation of Biogenerics. BioDrugs 18 (6), pages 399-406.
dc.relation.haspart Nieminen, O., Kurki, P. and Nordström, K., Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development. European Journal of Pharmaceutics and Biopharmaceutics, in press.
dc.subject.other Biotechnology en
dc.title Regulation of biopharmaceuticals, tissue engineering and biogenerics : key issues for the developer en
dc.type G5 Artikkeliväitöskirja fi
dc.description.version reviewed en
dc.contributor.department Department of Chemical Technology en
dc.contributor.department Kemian tekniikan osasto fi
dc.subject.keyword biopharmaceutical en
dc.subject.keyword regulation en
dc.subject.keyword EMEA en
dc.subject.keyword FDA en
dc.subject.keyword tissue engineering en
dc.subject.keyword biogeneric en
dc.subject.keyword risk management en
dc.subject.keyword biotechnology en
dc.identifier.urn urn:nbn:fi:tkk-005207
dc.type.dcmitype text en
dc.type.ontasot Väitöskirja (artikkeli) fi
dc.type.ontasot Doctoral dissertation (article-based) en
dc.contributor.lab Laboratory of Biochemistry and Microbiology en
dc.contributor.lab Biotekniikan ja mikrobiologian laboratorio fi

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search archive

Advanced Search

article-iconSubmit a publication